Alnylam Pharmaceuticals
ALNY
#601
Rank
โ‚ฌ31.45 B
Marketcap
243,91ย โ‚ฌ
Share price
4.37%
Change (1 day)
42.39%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚ฌ0.17 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚ฌ2.09 Billion. In 2023 the company made an earning of -โ‚ฌ0.31 Billion, an increase over its 2022 earnings that were of -โ‚ฌ0.95 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚ฌ0.17 Billion-44.53%
2023 -โ‚ฌ0.31 Billion-67.84%
2022 -โ‚ฌ0.95 Billion36.93%
2021 -โ‚ฌ0.69 Billion-8.04%
2020 -โ‚ฌ0.75 Billion-15.66%
2019 -โ‚ฌ0.89 Billion12.23%
2018 -โ‚ฌ0.8 Billion62.91%
2017 -โ‚ฌ0.49 Billion17.78%
2016 -โ‚ฌ0.42 Billion43.44%
2015 -โ‚ฌ0.29 Billion60.69%
2014 -โ‚ฌ0.18 Billion98.2%
2013 -โ‚ฌ90.32 Million
2011 -โ‚ฌ53.27 Million27.48%
2010 -โ‚ฌ41.79 Million-10.92%
2009 -โ‚ฌ46.91 Million95.77%
2008 -โ‚ฌ23.97 Million
2006 -โ‚ฌ38.39 Million-9.13%
2005 -โ‚ฌ42.25 Million34.74%
2004 -โ‚ฌ31.36 Million36.79%
2003 -โ‚ฌ22.92 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚ฌ0.57 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ4.82 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.12 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ0.12 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ40.2 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ12.37 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ7.19 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ0.40 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel